pulmonari
complic
import
caus
treatmentrel
morbid
mortal
hematopoiet
cell
transplant
hct
children
aim
studi
investig
yield
prehct
pulmonari
screen
program
also
describ
manag
guidelin
base
find
correl
symptomat
lung
injuri
hct
sinc
patient
undergo
dedic
pulmonari
screen
consist
pulmonari
function
test
pft
chest
highresolut
comput
tomographi
hrct
bronchial
alveolar
lavag
bal
hct
systemat
evalu
yield
first
year
screen
program
includ
consecut
children
patient
abnorm
found
patient
pft
result
normal
chest
hrct
show
abnorm
abnorm
consid
clinic
signific
bal
abnorm
patient
respiratori
virus
pcr
found
patient
fungi
antigen
cultur
bacteria
cultur
screen
test
contribut
separ
clinic
relev
inform
regard
pulmonari
statu
prehct
children
patient
screen
result
diagnost
andor
therapeut
implic
found
associ
presct
hrct
find
lung
injuri
transplant
prehct
screen
combin
modal
reflect
differ
domain
respiratori
statu
function
structur
microbi
colon
reveal
import
abnorm
substanti
number
patient
whether
improv
patient
outcom
requir
investig
hematopoiet
cell
transplant
hct
cur
treatment
variou
diseas
pulmonari
complic
infecti
noninfecti
frequent
seen
patient
undergo
hct
children
incid
pulmonari
complic
vari
associ
significantli
increas
risk
mortal
risk
lifethreaten
complic
procedur
patient
routin
screen
hct
elig
lung
screen
potenti
impact
select
hct
patient
well
affect
preemptiv
treatment
prognosi
invas
fungal
infect
ifi
import
caus
morbid
mortal
hct
diagnost
imag
cultur
pathogen
antigen
detect
help
identifi
patient
high
risk
ifi
may
guid
therapi
also
respiratori
virus
rv
may
impact
overal
surviv
hct
either
directli
caus
pneumon
sever
immunecompromis
patient
indirectli
trigger
alloimmun
set
allogen
transplant
implement
extens
prehct
lung
screen
includ
pulmonari
function
test
pft
chest
highresolut
comput
tomographi
hrct
bronchial
alveolar
lavag
bal
patient
evalu
yield
extens
pulmonari
screen
biolog
blood
marrow
transplant
j
u
r
n
l
h
e
p
g
e
w
w
w
b
b
r
g
program
describ
treatment
guidelin
accord
find
well
outcom
patient
consecut
pediatr
patient
undergo
first
allogen
hct
center
januari
august
includ
patient
enrol
hct
research
protocol
provid
written
inform
consent
data
collect
analysi
accord
nation
ethic
regul
ethic
commiss
number
patient
characterist
age
gender
underli
diseas
clinic
symptom
result
pulmonari
screen
test
occurr
symptomat
lung
diseas
hct
regist
standard
prehct
pulmonari
screen
perform
week
transplant
consist
pft
hrct
scan
bal
pft
includ
spirometri
whole
bodi
plethysmographi
measur
carbon
monoxid
diffus
capac
measur
perform
children
age
year
older
accord
american
thorac
societi
european
respiratori
societi
criteria
use
calibr
pneumotachomet
system
jaeger
hochberg
germani
valu
express
percentag
predict
valu
age
race
sex
heightmatch
control
utrecht
data
set
koopman
forc
expiratori
volum
second
forc
vital
capac
total
lung
capac
lung
diffus
capac
co
correct
hemoglobin
alveolar
volum
predict
valu
consid
abnorm
residu
volum
total
lung
capac
consid
abnorm
suggest
trap
air
hrct
scan
acquir
use
row
scanner
philip
medic
system
best
netherland
infant
young
children
scan
obtain
h
pressur
inspir
h
pressur
expir
older
children
abl
cooper
breath
hold
instruct
scan
obtain
full
inspir
end
exhal
inspir
imag
obtain
use
fix
kvp
ma
depend
bodyweight
expir
imag
use
kvp
ma
acquisit
volumetr
thinslic
inspiratori
expiratori
comput
tomographi
hrct
scan
assess
pediatr
radiologist
fleischner
societi
term
thorac
imag
use
abnorm
state
radiolog
report
regist
abnorm
clinic
implic
antimicrobi
treatment
guid
lung
biopsi
diuret
defin
clinic
signific
bal
perform
gener
anesthesia
bal
fluid
cultur
process
accord
standard
microbiolog
procedur
galactomannan
gm
test
perform
use
biorad
platelia
aspergillu
eia
posit
cultur
gm
level
consid
abnorm
nucleic
acid
extract
use
total
nucleic
acid
protocol
magna
pure
lc
nucleic
acid
isol
system
roch
diagnost
basel
switzerland
detect
rnavirus
cdna
synthes
use
multiscrib
revers
transcriptas
random
hexam
appli
biosystem
foster
citi
ca
detect
viral
atyp
pathogen
perform
parallel
use
realtim
pcr
assay
specif
follow
virus
bocaviru
human
respiratori
syncyti
viru
influenzaviru
b
parainfluenzaviru
rhinovirus
adenovirus
human
coronaviru
human
metapneumoviru
mycoplasma
pneumonia
realtim
pcr
procedur
perform
describ
previous
posit
pcr
consid
abnorm
total
cost
pulmonari
screen
approxim
euro
chest
hrct
cost
euro
rv
panel
pcr
bacteri
cultur
euro
gm
euro
pft
complet
cost
euro
analysi
patient
classifi
accord
risk
prehct
pulmonari
problem
base
underli
diseas
immun
compet
infect
risk
pretreat
potenti
lungtox
therapi
distinguish
group
patient
inherit
immun
defici
malign
diseas
chemotherapi
transplant
inborn
error
metabol
mild
bone
marrow
failur
malign
without
chemotherapeut
treatment
antibiot
prophylaxi
involv
daili
ciprofloxacin
fluconazol
start
condit
resolut
neutropenia
addit
prophylaxi
streptococcu
viridan
given
cefazolin
mucos
phase
empir
antibiot
treatment
febril
neutropenia
includ
vancomycin
ceftazidim
pneumocysti
jeroveci
pneumonia
prophylaxi
start
month
transplant
cotrimoxazol
time
week
case
posit
serolog
herp
simplex
viru
patient
case
posit
serolog
varicella
zoster
viru
cord
blood
transplant
recipi
prophylaxi
aciclovir
given
antivir
prophylaxi
given
patient
high
risk
ifi
accord
protocol
base
pretreat
durat
neutropenia
histori
fungal
infect
aspergillu
prophylaxi
given
daili
voriconazol
twice
weekli
amphotericin
b
patient
sever
impair
pft
normal
consid
unaccept
high
risk
treatmentrel
mortal
exclud
hct
patient
rv
bal
consid
high
risk
alloimmunemedi
lung
syndrom
elect
hct
procedur
hct
postpon
rv
clear
casesdwhen
underli
diseas
allow
treatment
delaydtap
immun
suppress
hct
adjust
prevent
alloimmunemedi
lung
syndrom
case
probabl
fungal
diseas
posit
cultur
gm
bal
antifung
treatment
consid
patient
posit
bacteri
cultur
bal
treat
unless
pulmonari
symptom
develop
bacteri
cultur
result
guid
choic
empir
antibiot
treatment
neutropen
fever
hct
patient
nodular
lesion
hrct
lung
biopsi
consid
identifi
possibl
infecti
caus
antimicrobi
resist
pattern
patient
possibl
proven
ifi
base
bal
find
biopsi
result
hrct
find
antifung
treatment
start
granulocyt
transfus
haploident
stem
cell
support
combin
cord
blood
graft
consid
calcul
mean
valu
standard
deviat
done
pft
compar
result
predict
valu
age
race
sex
heightmatch
control
done
use
ttest
test
valu
comparison
mean
differ
diseas
group
done
use
anova
chisquar
test
use
comparison
proport
group
differ
p
valu
consid
statist
signific
associ
prehct
pulmonari
screen
find
clinic
manifest
lung
injuri
hct
analyz
use
cox
proport
hazard
model
dichotom
outcom
use
depend
variabl
univari
predictor
p
valu
use
multivari
analysi
statist
done
use
spss
includ
consecut
children
receiv
first
allogen
hct
apart
mild
upper
respiratori
tract
symptom
patient
asymptomat
lung
diseas
time
prehct
screen
patient
characterist
shown
tabl
patient
presct
lung
screen
perform
month
age
patient
plan
screen
modal
could
perform
children
test
done
either
logist
reason
n
screen
bal
reason
gener
anesthesia
consid
disproport
invas
procedur
n
children
age
pft
feasibl
development
delay
patient
hrct
omit
risk
irradi
damag
relat
underli
diseas
fanconi
anemia
pft
perform
patient
patient
abl
perform
test
accord
age
development
level
result
shown
tabl
found
pft
pattern
restrict
obstruct
lung
diseas
well
diffus
abnorm
forc
expiratori
volum
second
mean
sd
forc
vital
capac
mean
sd
total
lung
capac
sd
lung
diffus
capac
co
correct
hemoglobin
alveolar
volum
sd
compar
refer
popul
valu
sd
differ
statist
signific
p
valu
differ
abnorm
pft
differ
diseas
categori
see
tabl
chest
hrct
perform
patient
patient
abnorm
seen
patient
find
new
find
group
patient
without
pretreat
chemotherapi
immun
defici
incid
hrct
abnorm
hct
significantli
lower
patient
figur
patient
clinic
signific
abnorm
found
four
lesion
suspect
fungu
fourteen
patient
show
abnorm
includ
bronchiectasi
pleural
effus
consolid
aspecif
nodul
cm
new
find
patient
clinic
signific
abnorm
found
subgroup
patient
immun
defici
reach
statist
signific
figur
bal
perform
patient
unfortun
logist
reason
alway
possibl
microbi
test
overal
test
patient
microbi
test
posit
posit
pcr
rv
found
test
patient
rhinoviru
frequent
detect
viru
tabl
patient
found
microbi
evid
fungal
colon
either
posit
cultur
gm
patient
posit
gm
correspond
posit
cultur
aspergillu
patient
posit
aspergillu
cultur
gm
bal
neg
posit
find
whole
cohort
shown
tabl
patient
year
age
incid
bal
abnorm
gener
rv
posit
bacteria
posit
signific
higher
older
patient
p
valu
respect
figur
show
yield
screen
test
abnorm
found
test
patient
found
abnorm
radiolog
test
among
patient
normal
abnorm
pft
well
posit
microbi
test
result
patient
normal
pft
normal
hrct
patient
screen
outcom
implic
guid
ballung
biopsi
n
chang
antifung
treatmentprophylaxi
n
granulocyt
transfus
n
addit
haploident
stem
cell
n
postpon
hct
n
guid
taper
immun
suppress
agent
n
intervent
overlap
patient
patient
prehct
hrct
show
new
progress
sign
infiltr
fungal
infect
antifung
therapi
intensifi
base
resist
pattern
cultur
pathogen
patient
postpon
hct
cord
blood
transplant
recipi
ad
haploident
cell
famili
donor
earli
myeloid
support
patient
gave
granulocyt
transfus
period
neutropenia
one
patient
graft
reject
show
fatal
progress
aspergillu
infect
prolong
neutropenia
other
show
progress
infect
therapi
could
stop
safe
engraft
patient
rv
bacteria
isol
show
progress
pulmonari
infect
hct
none
patient
isol
posit
find
fungu
bal
major
receiv
intensif
fungal
prophylaxi
treatment
develop
pulmonari
fungal
diseas
cox
regress
analysi
show
relat
prehct
screen
find
bal
pft
symptomat
lung
injuri
hct
clinic
signific
abnorm
chest
hrct
hct
howev
predictor
develop
immunemedi
lung
injuri
hct
hazard
ratio
confid
interv
p
studi
pediatr
patient
show
pulmonari
screen
hct
pft
hrct
bal
feasibl
could
perform
test
major
patient
abnorm
found
patient
galactomannan
bal
posit
overlap
fungal
cultur
result
galactomannan
find
bal
aspergillusposit
patient
also
galactomannan
posit
patient
candida
penicillium
also
posit
gm
patient
consid
posit
fungu
patient
abnorm
led
supportivepreempt
treatment
accord
guidelin
patient
clinic
signific
chest
hrct
abnorm
higher
incid
lunginjuri
note
hct
although
neglig
cost
seem
justifi
relat
find
well
known
pulmonari
function
declin
earli
hct
studi
shown
continu
declin
without
reach
plateau
prolong
followup
sever
studi
demonstr
impair
pft
transplant
increas
risk
posttransplant
lung
complic
mortal
possibl
explan
observ
patient
margin
lung
reserv
capac
endang
period
critic
ill
andor
lung
toxic
event
also
patient
preexist
lung
injuri
organ
may
increas
risk
alloimmun
phenomena
graftversushost
diseas
evalu
yield
hrct
scan
omit
hrct
screen
cohort
would
miss
children
abnorm
includ
infiltr
lesion
suspect
fungu
hand
hrct
lead
radiat
exposur
may
requir
gener
anesthesia
children
therefor
deserv
critic
apprais
relev
abnorm
find
hrct
matter
debat
radiolog
report
studi
abnorm
describ
patient
sever
report
abnorm
vari
consider
chose
take
account
hrct
find
signific
clinic
mean
time
transplant
consolid
requir
antibiot
antifung
therapi
bronchiectasi
risk
factor
infect
warrant
chang
prophylaxi
pleural
effus
requir
diuret
patient
plain
chest
xray
avail
show
abnorm
note
show
abnorm
patient
sign
invas
fungal
infect
hrct
data
shown
yield
bal
procedur
high
studi
omit
bal
would
miss
patient
fungal
colon
rv
patient
normal
hrct
scan
signific
pulmonari
symptom
figur
illustr
test
contribut
separ
inform
regard
pulmonari
statu
prehct
children
argu
screen
modal
reflect
differ
domain
respiratori
statu
function
structur
microbi
colon
done
pediatr
prehct
patient
sensit
prehct
screen
pulmonari
patholog
desir
impact
find
invas
test
guid
clinician
decisionmak
whether
perform
test
far
know
first
report
comprehens
pulmonari
screen
pft
hrct
bal
larg
cohort
children
hct
shown
consider
decreas
pulmonari
function
signific
amount
clinic
import
hrct
find
high
preval
infecti
agent
like
underli
diseas
pretreat
chemotherapi
age
distribut
patient
cohort
patient
signific
associ
clinic
signific
hrct
find
hct
lung
injuri
hct
find
bal
pft
relat
outcom
might
due
small
number
might
also
conclud
current
treatment
strategi
group
pulmonari
compromis
patient
manag
compar
outcom
conclud
screen
protocol
feasibl
provid
import
inform
risk
classif
therapeut
consequ
would
advoc
screen
method
contribut
separ
prospect
studi
need
identifi
import
baselin
abnorm
risk
pulmonari
complic
treatmentrel
mortal
whether
outcom
improv
use
intens
screen
financi
disclosur
statement
item
disclos
conflict
interest
statement
conflict
interest
report
authorship
statement
abv
full
access
data
studi
take
respons
integr
data
analysi
cke
jjb
tw
pdj
mb
contribut
equal
substanti
studi
design
interpret
data
write
manuscript
